{"url_path":"/sec/nmra/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","accession_number":"0001193125-26-270328","cik":"0001885522","ticker":"NMRA","issuer_name":"Neumora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","primary_entity_key":"0001885522","primary_entity_name":"Neumora Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\nExhibit No.\n\n  \n\nDescription\n\n99.1\n  \n[Press release of Neumora Therapeutics, Inc. dated June 15, 2026.](d943192dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nNEUMORA THERAPEUTICS, INC.\n\nDate: June 15, 2026\n \n\n \nBy:\n \n\n/s/ Michael Milligan\n\n \n\n \n\n \nMichael Milligan\nChief Financial Officer"}